Eliquis vs. Savaysa

See how Eliquis and Savaysa compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Eliquis is taken twice daily and covers more approved uses, including surgical DVT prevention and pediatric VTE treatment.

  • Savaysa is a once-daily pill but is not recommended for atrial fibrillation patients with very strong kidney function.

  • Both drugs are factor Xa inhibitors that raise bleeding risk and carry a boxed warning against stopping treatment early.

Eliquis vs. Savaysa Drug Summary

Eliquis

Eliquis (apixaban) is a factor Xa inhibitor anticoagulant used to prevent stroke in atrial fibrillation, prevent and treat blood clots (DVT/PE), and reduce clot risk after hip or knee replacement. It is taken as a tablet twice a day, with dosing that varies by indication and patient risk factors.

Savaysa

Savaysa (edoxaban) is a factor Xa inhibitor anticoagulant used to prevent stroke in atrial fibrillation and to treat DVT and PE. It is taken as a single tablet once a day, usually after several days of an injectable blood thinner when starting treatment for DVT or PE.

Eliquis vs. Savaysa Side Effects

Eliquis

Most common
Epistaxis (up to 2.9%)
Contusion (up to 1.8%)
Hematuria (up to 1.7%)
Menorrhagia (up to 1.4%)

Savaysa

Most common
Bleeding (up to 21.7%)
Clinically relevant non-major bleeding (up to 18.1%)
Anemia (up to 9.6%)
Abnormal liver function tests (up to 4.8%)

Eliquis vs. Savaysa Dosage

Eliquis

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg twice daily Days 1-7
Maximum dose 2.5 mg twice daily If needed
Dose changes 1 increase As tolerated

Savaysa

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 30 mg once daily At the start
Maximum dose 30 mg once daily Same as starting
Dose changes None Fixed dose

Eliquis vs. Savaysa Indications

Eliquis

Eliquis is FDA-approved for a broad range of clotting conditions, from stroke prevention in atrial fibrillation to surgical clot prevention and pediatric clot treatment. It also carries the widest age range of any oral factor Xa inhibitor, with pediatric dosing approved from birth.

  • Reduce stroke and systemic embolism risk in nonvalvular AFib

  • Prevent DVT after hip or knee replacement surgery

  • Treat DVT and PE

Savaysa

Savaysa is FDA-approved for stroke prevention in atrial fibrillation and for treating DVT and PE in adults. It is not approved for surgical clot prevention, pediatric use, or patients with very strong kidney function.

  • Reduce stroke and systemic embolism risk in nonvalvular AFib

  • Treat deep vein thrombosis (DVT)

  • Treat pulmonary embolism (PE)

Eliquis vs. Savaysa Pros and Cons

Eliquis

Eliquis covers more approved uses than Savaysa, including surgical DVT prevention and pediatric clot treatment, and it has a specific reversal agent available for bleeding emergencies. The tradeoff is a twice-daily pill instead of a once-daily one.

Pros

  • Approved for DVT prevention after hip or knee surgery

  • Approved for pediatric VTE treatment from birth

  • No restriction based on excellent kidney function

Cons

  • Must be taken twice a day instead of once

  • Requires dose adjustment across multiple criteria (age, weight, kidney function)

  • Carries a boxed warning about spinal or epidural blood clots during certain procedures

Savaysa

Savaysa offers the convenience of one pill a day, but it comes with a boxed warning against use in atrial fibrillation patients whose kidneys clear the drug too efficiently. It also covers fewer approved indications than Eliquis.

Pros

  • Only needs to be taken once a day

  • Simpler two-dose maintenance schedule (60 mg or 30 mg)

  • No initial loading-dose titration needed

Cons

  • Not recommended for AFib patients with CrCL above 95 mL/min

  • Not approved for surgical clot prevention or pediatric use

  • Requires 5 to 10 days of injectable anticoagulant before starting for DVT/PE

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.